Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.39 |
| ▸ | PDE4A | P27815 | 8/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551646 | 0.99 | ALDH1A1 (0.42) | ALDH1A1TSHRMEN1HTTKMT2A | |
| SCHEMBL3546085 | 0.95 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2APDE4BPDE4A | |
| SCHEMBL3547192 | 0.89 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2APDE4BPDE4A | |
| SCHEMBL3548446 | 0.89 | ALDH1A1 (0.44) | ALDH1A1PDE4BPDE4AHPGDPDE4C | |
| SCHEMBL4476175 | 0.89 | PDE4A (0.42) | ALDH1A1TSHRMEN1HTTKMT2A | |
| SCHEMBL4463376 | 0.88 | PDE4A (0.42) | ALDH1A1TSHRMEN1HTTKMT2A | |
| SCHEMBL3539484 | 0.86 | MEN1 (0.43) | ALDH1A1TSHRMEN1KMT2APDE4B | |
| SCHEMBL3549160 | 0.86 | ALDH1A1 (0.43) | ALDH1A1PDE4BPDE4AHPGDPDE4C | |
| SCHEMBL3548409 | 0.86 | PDE4A (0.42) | ALDH1A1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3544869 | 0.86 | PDE4A (0.43) | ALDH1A1PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613590-A2 | 4-(3,4-DISUBSTITUTED PHENYL)-PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004094375-A2 | 4 - (3,4 - DISUBSTITUTED PHENYL) - PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | claimed |
| US-7696198-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| WO-2009067607-A2 | COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | MEMORY PHARMACEUTICALS CORPORATION | 2006-06-22 | — | — | US | disclosed |
| EP-1613590-A2 | 4-(3,4-DISUBSTITUTED PHENYL)-PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050026913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-2004094375-A2 | 4 - (3,4 - DISUBSTITUTED PHENYL) - PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE12, PDE3B | ALDH1A1 132/4885TSHR 1786/4885MEN1 3290/4885 |
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | PDE4A, PDE4B, PDE12 | ALDH1A1 448/4885TSHR 2129/4885MEN1 865/4885 |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE5A | ALDH1A1 395/4885TSHR 2737/4885MEN1 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.